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The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are
morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we
conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affy-
metrix GeneChip® Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were
shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common
to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events
across the genome than ILC (fractional allelic loss 5 0.186 and 0.156). By comparing the average frequency of LOH by chro-
mosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q
than ILC tumors. We identified additional chromosomal arms differentiating the subtypes when tumors were stratified by tu-
mor size, mitotic rate, or DNA content. Of 5,754 informative SNPs (>25% informativity), we identified 78 and 466 individual
SNPs with a higher frequency of LOH (P < 0.05) in ILC and IDC tumors, respectively. Hierarchical clustering of these 544
SNPs grouped tumors into four major groups based on their patterns of LOH and retention of heterozygosity. LOH in chro-
mosomal arms 8p and 5q was common in higher grade IDC tumors, whereas ILC and low-grade IDC grouped together by vir-
tue of LOH in 16q. Published 2008 Wiley-Liss, Inc.†
INTRODUCTION
Infiltrating lobular carcinoma (ILC) differs both
morphologically and clinically from the more com-
mon infiltrating ductal carcinoma (IDC) in breast
cancer. ILC is more likely to be bilateral, multicen-
tric, and diploid than IDC. Also, ILC tumors have a
pattern of metastasis to bone, gastrointestinal tract,
and ovary that is different from that of IDC (Harris
et al., 1984; Arpino et al., 2004). The widely infiltra-
tive growth of individual and small rows of lobular
cancer cells through breast stroma results in a low
detection rate by clinical exam or by mammog-
raphy (Porter et al., 1999). Given that ILC typically
has favorable prognostic indicators (Arpino et al.,
2004), a more favorable relationship with survival
and recurrence would be expected. A survival
advantage has been associated with good prognosis
in some studies but not in others (Mersin et al.,
2003; Li et al., 2003b; Arpino et al., 2004; Cristofa-
nilli et al., 2005), indicating that other, as yet
unknown, factors might distinguish ILC from IDC.
Historically, ILC has accounted for between 5
and 14% of breast cancers (Harris, et al., 1992), but
recent analyses of Surveillance Epidemiology and
End Results (SEER) data indicate that ILC inci-
dence rates have increased rapidly over the past
two decades in the United States (Li et al., 2003a),
primarily in women over age 50. This differential
increase in older women is in keeping with recent
studies that have implicated combined (estrogen/
progestin) hormone replacement therapy (CHRT)
as a risk factor for lobular type breast cancer
(Chen et al., 2002; Li et al., 2003b: WHI Steering
Committee 2004).
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Although a few studies have compared molecu-
lar alterations between the two subtypes and have
generated some information about differences in
the frequency and locations of genomic alterations,
the small number of ILC tumors and the limited
number of loci interrogated in most studies have
limited the comprehensive evaluation of genomic
differences between ILC and IDC (Gunther et al.,
2001; Loo et al., 2004; Roylance et al., 2006).
One of the most common alterations in breast
cancer is allelic imbalance or loss of heterozygosity
(LOH). An LOH event can be associated with
either a gene copy number loss or amplification.
LOH has been shown to occur in precancer lesions
of the breast and in normal epithelium of women
with breast cancer (Deng et al., 1996; O’Connell et
al., 1998). The profile of the most common LOH
events in breast cancer includes losses in chromo-
some arms, 1q, 3p, 6q, 11p, 13q, 16q, 17p, 17q, and
18q (Devilee and Cornelisse, 1994), but the contri-
bution that ILC makes to that overall profile is
small, given the low number of lobular cancers
included in virtually all studies assessing allelic
imbalance.
To gain a better understanding of allelic imbal-
ance events inherent in the lobular subtype of
breast cancer, we compared LOH profiles of flow
cytometrically sorted ER-positive ILC and IDC
tumors derived from a population-based sample.
Restricting the analysis to ER-positive tumors
allowed us to assess similarities and differences in
LOH events between the subtypes not con-
founded by differences due to the ER status of the
tumors.
MATERIALS ANDMETHODS
Patient Population
Participants in this study were drawn from a
population-based case–control study designed to
examine the relationships of risk factors and histo-
logical type of breast cancer. The methods used to
select, enroll, and interview participants have been
described in detail elsewhere (Li, et al., 2008).
The study included ILC (ICD-O histology code
8520/3) and IDC cases (ICD-O histology code
8500/3) 55–74 years of age, ascertained through our
population-based cancer registry for 13 western
Washington counties and diagnosed between Janu-
ary 2000 and March 2004. This analysis was re-
stricted to the 77 ILC and 89 IDC cases for whom
we had sufficient tumor tissue to conduct this work
and who had an available blood specimen. All par-
ticipants consented to tumor- and blood-sample
testing.
Pathology Review for Histological
Diagnosis/Tumor Characteristics
To verify histological diagnoses for all tumors,
pathology reports and histology slides underwent
centralized pathology review by the four patholo-
gists (PLP, MGL, XY, TL), using published criteria
for ILC and IDC tumors (Page and Anderson,
1987). Histological grade was assessed for IDC
tumors using the Nottingham grading scheme
(Elston and Ellis, 1991). After agreement by all
study pathologists on diagnostic criteria, the histol-
ogy of each case was assessed by review of all sub-
mitted slides by one of two staff pathologists
(MGL, XY). A second review of the diagnosis and
histological grade of each case was done by the
study pathologist (PLP). Discrepancies between
the initial and second assessments were resolved
by consensus review or submitted for additional
review to the study’s consulting pathologist (TL).
All reviews were conducted independently.
The components of clinical stage: tumor size,
lymph node metastasis, and distant metastasis
were obtained from SEER and/or original pathol-
ogy reports.
Immunohistochemistry
To verify the steroid-receptor status of all
tumors, immunohistochemistry (IHC) for the
expression of estrogen receptor (ER) (ER1D5,
AMAC, Inc) (Andersen and Poulson, 1989) and
progesterone receptor (PR) (1A6 NovoCastra Lab)
(Giri et al., 1988) was done on a representative
block for each tumor using standard IHC techni-
ques including antigen retrieval (Hsu et al., 1981;
Taylor et al., 1994). Positive and negative controls
were included for each antibody.
Flow Cytometric Cell Sorting and DNA Extraction
Tumor cells were collected by flow sorting based
on cytokeratin and DNA content, which enriches
the sample for tumor cells while excluding contam-
inating stromal and lymphocytic cells as described
previously (Glogovac et al., 1996). Cell populations
were classified as diploid/near diploid (1.0  DNA
Index (DI)  1.39) and aneuploid (DI > 1.39 or DI
< 1.0). If a tumor contained multiple populations
with different ploidy, the most prevalent aneuploid
population was assayed. DNA was extracted from
the sorted tumor cells (a minimum of 100,000 cells
per tumor) using the QIAamp DNA Micro kit
(Qiagen, Valencia, CA) with modifications. Briefly,
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tumor cells were extracted in Qiagen ATL buffer
with the addition of proteinase K (20 lg/ll), and
two additional proteinase K applications at 6 and
24 hr, while being mixed at 350 rpm (Eppendorf
Thermomixer R, Westbury, NY) at 568C for a total
of 45 hr. Tumor DNA was then extracted based
on the manufacturers’ recommendation. We quan-
tified tumor genomic DNA by real-time PCR
(Applied Biosystems, Foster City, CA) using two
chromosome 2 specific probes at 2p25.3 (29,907–
30,162) and 2q31.1 (21,407,882–21,408,181) with
normal human female genomic DNA (Promega,
Madison, WI) as the reference. Normal genomic
DNA from peripheral blood lymphocytes (PBLs)
was extracted and purified with the QIAamp DNA
Blood Midi Kit (QIAGEN, Valencia, CA), DNA
from the tumor cell sample and the blood sample
from each subject was aliquoted and stored at
-808C prior to assay.
SNPArray Assay
The GeneChip1 Mapping 10K Assay (Affyme-
trix, Santa Clara, CA), or Map 10K array, was per-
formed as recommended by the manufacturer.
Two DNA samples from each woman (tumor and
PBL) were assayed on separate arrays. Purified
genomic DNA (200–250 ng) was digested with the
XbaI restriction enzyme, and then amplified by li-
gation-mediated PCR. As recommended by the
manufacturer, multiple PCR reactions were pooled
more if necessary for the formalin fixed paraffin
embedded (FFPE) samples, to obtain 20 lg of
PCR product for labeling and hybridization to the
GeneChip1 Human Mapping 10K Array Xba131
Version 1.0 (40 tumors) or Xba 142 Version 2.0 (126
tumors). Arrays were scanned with an Affymetrix
GeneChip Scanner 3000 7G using GeneChip
Operating System (GCOS) 1.3 and analyzed with
Affymetrix GeneChip1 DNA Analysis Software
(GDAS) 3.0. Version 1.0 and Version 2.0 share
9,706 SNPs, which were analyzed here. The
genetic map used in the analysis was obtained
from GeneChip Mapping 10K library files: Map-
ping10K_Xba131 or Mapping10K_Xba142.
To ensure that the DNA from FFPE samples
was compatible with the Map 10K array, we tested
DNA from paired fresh and FFPE samples of four
human cell lines (X-chromosome aneusomy cell
lines, Coriell Cell Repositories, Camden NJ) on
the array. The FFPE samples were processed
using the same procedures as those used for tumor
samples including embedding in paraffin. There
was high concordance for the genotype calls
(99%) between the matched FFPE and frozen
samples and excellent reproducibility in four sam-
ples done in duplicate on different days (data not
shown).
Short Tandem Repeat (STR) Validation Assays
To validate the array findings, we assayed for
LOH using microsatellite markers (short tandem
repeats or STRs) for multiple locations of a subset
of the 166 cases. Seventy tumor samples were
assayed with fluorescent primers (Operon Technol-
ogies, Alameda, CA) and standard PCR reactions,
for the following STR markers in these chromo-
somal locations: 2q34.35 (D17S1322 and D17S932),
16q22.1 (D16S767 and D17S932), and 17q21
(D2S2319 and D16S767). Forty-three tumor sam-
ples were assayed at 6q25.1 (D16S496). DNA from
PBLs served as the constitutive normal genomic
DNA for comparison with tumor sample. Primer
sequence, map location (in Mb), and additional in-
formation associated with the STR markers can be
obtained at National Center for Biotechnology In-
formation (NCBI; http://www.ncbi.nlm.nih.gov/).
Statistical Analysis
An LOH event at a specified SNP for a tumor
was defined as a SNP with a heterozygous (AB)
genotype in the constitutive blood DNA and
homozygous (AA or BB) genotype in the tumor.
Genome-wide fractional allelic loss (FAL) was cal-
culated by taking the ratio of the number of SNPs
exhibiting LOH and the total number of informa-
tive SNPs in the whole genome for each tumor.
FAL was also calculated for each chromosomal arm
by using the SNPs on that arm only. Two-sample t
statistics were used to assess the significance of the
mean differences of FAL between ductal and lobu-
lar subtypes and following stratification by the
categorized DI (diploid/near diploid versus aneu-
ploid), mitotic rate (low versus intermediate or
high), and tumor size T1a/T1b (2.0 cm), T1c
(2.1–5.0 cm), and T2/T3, (>5.0 cm). The two-sam-
ple t statistics were also used to assess the associa-
tion of FAL with DI and mitotic rate stratified by
ILC and IDC status. The F-test was used to assess
FAL in relation to tumor size stratified by ILC and
IDC status.
The association of LOH at individual SNPs with
lobular and ductal subtypes was also examined
using a likelihood-ratio test statistic based on the
logistic regression model. SNPs with informativity
less than 25% across tumors were excluded to
ensure an adequate sample size. The validity of
this test statistic for our data was examined by ran-
domly permuting the ILC and IDC status of these
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tumors while maintaining the same informativity
and frequency of LOH for each SNP. The P values
were uniformly distributed, indicating that the test
statistic is adequate in testing the differences of
LOH frequencies at each SNP between ILC and
IDC tumors with our data (results not shown).
Genesis (http://genome.tugraz.at) was used for
hierarchical clustering to group tumors based on
the SNPs that show significant differences in LOH
between ILC and IDC at level 0.05.
P values in all results are two-sided and consid-
ered statistically significant if they were less than
0.05 level. For individual SNP and subtype associ-
ation, the proportion of SNPs of statistical signifi-
cance at level 0.05 was compared to the expected
proportion of false positives when no association
exists between LOH and breast cancer subtypes.
Because this study will be used to generate
hypotheses for future studies, multiple comparison
adjustment was not explicitly performed. This
minimized the number of false negative results.
All analyses were performed using an OpenSource
R package which can be downloaded at http://
www.r-project.org/.
The software dCHIP was used to obtain copy
number (CN) information for each SNP (Lin et al.,
2004). The Circular Binary Segmentation (CBS)
method (Olshen et al., 2004) was used to smoothen
the original copy number data into segments of
similar copy number. CBS is a modified binary seg-
mentation procedure to find two change-points at a
time by considering the spliced segment as a circle.
The R package DNAcopy (http://bioconductor.org/)
was used for this procedure with the recommended
default settings, with one exception, alpha was set
as 0.05. Segmented copy number was categorized
as ‘‘Gain’’ (CN  3.0), ‘‘No Change’’ (1.0 < CN <
3.0), and ‘‘Loss’’ (CN  1.0), assuming diploid
CN 5 2.0.
RESULTS
Clinical Characteristics of the Lobular
and Ductal Tumors
One hundred and sixty-six (77 ER-positive ILC
and 89 ER-positive IDC) women with ER-positive
breast cancer tumors in the parent population
study had DNA yield and quality sufficient for
array testing. Within the group of Map10K-tested
tumors, the ILC tumors were more likely than the
IDC tumors to be larger, to exhibit a lower mitotic
rate, and to have diploid/near diploid DNA content
(Table 1). IDC and ILC tumors in the tested group
did not differ significantly with respect to stage of
disease, lymph node status, histological grade, or
PR status. To determine the relevance of the
results reported here to the general population of
women with breast cancer, we compared the char-
acteristics of the tested and untested IDC and ILC
groups. The tested IDC tumors were more likely
to have a higher stage (P 5 0.02), higher histologi-
cal grade (P 5 0.02), and higher mitotic rate (P 5
0.01) than the untested IDC group. There were no
statistically significant differences between the
tested and untested ILC tumors.
Reproducibility and Accuracy of LOH Identification
from Archival Samples by Map 10K Array
To test the accuracy of LOH calls by the Map
10K array for the FFPE tumor samples, we per-
formed STR genotyping at loci in or near four
genes: 70 tumor/control pairs at BRCA1 (17q21),
CDH1 (E-cadherin; 16q22.1), and BARD1
(2q34.35), and 43 tumor/control pairs at ESR1
(6q25.1). The LOH calls for each STR were com-
pared on a case-by-case basis to infer calls by the
Map 10K based on the flanking SNPs. The concor-
dances in LOH calls by Map 10K array and STR
were: BRCA1 (D17S1322) 89%, (D17S932) 85%;
CDH1 (D16S767) 100%, (D17S932) 100%; BARD1
(D2S2319) 100%, (D16S767) 100%; and ESR1
(D16S496) 96%. The strong concordance of the
LOH calls from the Map 10K array with an alterna-
tive and established method for determining
regions of LOH supported our confidence in the
identification of LOH with the Map 10K array.
We examined the SNP call rate as a measure for
the performance of the Map 10K Array for the 166
archival ER-positive breast tumors. The call rate
was defined as the percentage of SNPs given a ge-
notype call (‘‘AB,’’ ‘‘AA,’’ or ‘‘BB’’) on the array and
was generated automatically for each array by the
GDAS software. Similar to a previous report
(Thompson et al., 2005), the SNP call rates in this
study were comparatively lower for the FFPE sam-
ples (median call rate 86%; range 60–99%) than the
constitutive normal PBL samples (median call rate
97%; range 82–100%). This was likely due to the
compromised quality and quantity of DNA from
the FFPE samples compared to the frozen, non-
FFPE, constitutive normal PBL DNA.
Sites of High Frequency LOH in ER-Positive ILC
and IDC tumors
SNPs showing high frequency of LOH (informa-
tivity > 25% and with LOH frequency  50%)
were identified in ILC (165 SNPs) and in IDC
(200 SNPs) (Supplemental Data 1). Table 2 shows
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the cytogenetic band locations of the SNPs with
high frequency LOH for ILC and IDC tumors. We
observed SNPs with high frequency LOH that
were common to both histological subtypes (SNPs
in 11q, 16q, and 17p) and as has been reported pre-
viously, we observed these regions of common
LOH events were associated with copy number
‘‘loss’’ and ‘‘no change’’ (Carter et al., 1994; Tom-
linson et al., 1996; Roylance et al., 2006). There
were also SNPs for which LOH occurred predomi-
nantly and frequently in ILC (6q) or in IDC (8p,
13q). These results indicate that ILC and IDC
ER-positive tumors share common sites of high
frequency LOH in addition to LOH events occur-
ring primarily in one histological subtype and not
the other.
Differential LOH Frequencies Between ER-Positive
ILC and IDC Tumors
To characterize further the differences in the
frequency and location of LOH events between
IDC and ILC, we calculated the average genome-
wide FAL for both tumor types. We found IDC
had only slightly more LOH events than ILC
tumors (FAL 5 0.186 vs. 0.156, respectively). The
distribution of FAL across the genome for the two
subtypes differs in shape: the tumors in the upper
quartile range have fewer LOH events in ILC than
IDC (FAL 5 0.204 and 0.499, respectively),
although the distributions have nearly identical
medians (FAL 5 0.152 and 0.151 for ILC and
IDC, respectively) (Fig. 1A).
We compared the average FAL for ILC and IDC
for each chromosomal arm. Several chromosomal
arms showed a relatively high frequency of LOH
events (>25% FAL) for both ILC and IDC (6q,
11q, 16q, 17p, and 22q), consistent with what was
observed above in the genomic distribution of indi-
vidual high-frequency LOH SNPs, but we also
observed that IDC tumors have a significantly
higher frequency (P < 0.05) of FAL than ILC on
3p, 5q, 8p, 9p, 20p, 20q (Fig. 1B). Several chromo-
somal arms had a higher frequency of FAL for ILC
(1q, 6q, 16p and q, and X) but the differences were
TABLE 1. Clinical and Tumor Characteristics Among ER-Positive IDC and ILC Carcinomas Not Tested or Tested by the
Map10K Assay
Tumor marker
Not-MAP 10K tested ER1 cases MAP10K tested ER1 cases
IDC
(n5 234)
ILC
(n5 141)
P-valuea
IDC vs. ILC
IDC
(n5 89)
ILC
(n5 77)
P-valuea
IDC vs. ILCn % n % n % n %
AJCC stage
I 152 66 68 48 44 49 33 43
II 71 31 58 41 42 47 38 49
III/IV 9 4 15 11 <0.0001 3 3 6 8 0.23
Tumor size (cm)
T1a/T1b 167 77 75 56 57 66 38 50
T1c 44 20 47 35 27 31 28 37
T2/T3 7 3 13 10 <0.0001 2 2 10 13 0.008
Lymph node status
Negative 165 72 90 65 55 63 42 57
Positive 64 28 48 35 0.17 33 38 32 43 0.46
Histologic grade
Low 114 49 68 48 32 36 26 34
Intermediate 93 40 70 50 39 44 47 61
High 27 12 3 2 0.19 18 20 4 5 0.21
Mitotic rate
Low 181 77 134 95 55 62 71 92
Intermediate 34 15 6 4 21 24 5 7
High 19 8 1 1 <0.0001 13 15 1 1 <0.0001
Ploidy
Diploid/near diploid 86 58 74 68 52 58 62 81
Aneuploid 63 42 35 32 0.1 37 42 15 20 0.003
PRb
Positive 204 88 114 82 84 94 71 93
Negative 28 12 25 18 0.12 5 6 5 7 0.8
achi square P-value.
bAllred score <3, negative; 3, positive.
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TABLE 2. SNPs with High Frequency LOH (50% Fractional Allelic Loss)
Chromosomal
arm
Cytogenetic
band
ILC IDC
Genes 100 kb up or downstream
of SNPs with high frequency LOH
Number of SNPs
with high
frequency LOH
in the cytoband
Number of SNPs
with high
frequency LOH
in the cytoband
1p 1p36.12 1 C1QB, EPHA8, ZBTB40, C1QA, C1QC
3p 3p26.1a 1 1 GRM7
3p14.2 2 CADPS
3p14.1 1 MAGI1
3q 3q21.3 1 UROC1, AB113648, BC042038, BC103896,
C3orf22, CHST13
3q29a 1 1 FGF12, C3orf59
5q 5q23.2 1
6p 6p12.3 1 1 OPN5, FLJ41841
6q 6q12 1 PTP4A1
6q13 2 BAI3, RIMS1
6q14.1 1 2 HTR1B
6q16.1 1
6q16.3 1
6q21 2 1 SEC63, OSTM1, LOC442247
6q22.2 1 DCBLD1, ROS1
6q22.31 2 HSF2, SERINC1
6q23.3 1 HBS1L, ALDH8A1
6q24.3 1 STXBP5, BC107737
6q25.1 1 1 C6orf71, PPP1R14C
6q25.2 3 VIP
6q26 1 2 PARK2, PACRG, QKI
8p 8p23.3 1 MYOM2
8p23.2 3
8p23.1 7 ANGPT2, MCPH1, DEFA4, DEFA6, DEFA1, DEFB1,
PPP1R3B, THEX1, AY203962, AB073660, XKR6,
AJ307469, C8orf16, C8orf15
8p22a 1 11 SGCZ, TUSC3, MSR1, BC098128, FGF20, EFHA2,
VPS37A, MTMR7, AY176665, PSD3
8p21.3 2 C8orf58, BIN3, KIAA1967, SORBS3, PPP3CC,
PDLIM2
8p21.2 5 DOCK5, EBF2, AK130123, AY700779, AK130123
8p21.1 4 ESCO2, CCDC25, SCARA3, PBK, ELP3, ZNF395,
PNOC, RC74, FLJ21616, EXTL3
8p12 1 WRN, PURG
8q 8q11.23 1 OPRK1
9q 9q31.1 1 PPP3R2, GRIN3A
10q 10q21.1 1 PCDH15
11q 11q14.1 1 DLG2
11q14.2 1
11q14.3 1
11q21a 3 2 FAM76B, CEP57, MTMR2, MAML2, AY358248
11q22.1a 2 4 CNTN5, PGR, AK057372, AD031, KIAA1377,
ANGPTL5
11q22.2 1 MMP7, MMP8, MMP20, MMP27
11q22.3a 7 6 AB231766, MMP13, DCUN1D5, AB082528,
AB231766, BC037496, BX538093, DDI1, PDGFD
11q23.1a 4 4 ARHGAP20, BTG4, POU2AF1, FLJ46266,
AK096925, LAYN, BTG4, FLJ46266
11q23.2 3 DRD2, TTC12, AK125909, ANKK1, ZBTB16
11q23.3 2 BACE1, DSCAML1, PCSK7, DKFZp547C195,
CEP164, ARHGEF12
11q24.1 3 5 SORL1, BRCC2, ASAM, OR4D5, OR10S1,
PMP22CD, LOH11CR2A, OR10G7, OR10G8
(Continued)
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TABLE 2. SNPs with High Frequency LOH (50% Fractional Allelic Loss) (Continued)
Chromosomal
arm
Cytogenetic
band
ILC IDC
Genes 100 kb up or downstream
of SNPs with high frequency LOH
Number of SNPs
with high
frequency LOH
in the cytoband
Number of SNPs
with high
frequency LOH
in the cytoband
11q24.2 3 3 PKNOX2, AK055281, FEZ1, MGC39545, CHEK1,
ACRV1, STT3A, KIRREL3
11q25 1 3 HNT, OPCML
12p 12p13.31 1 PZP
12p11.22 1 AF113698, MLSTD1
12q 12q24.21 1
12q24.33a 1 1 KIAA1944
13q 13q12.12a 1 1 SPATA13
13q14.11 1
13q21.1 2 PCDH17
13q21.32 2
13q31.1 1
13q31.2 1
13q31.3 1
13q33.1 1 FGF14
14q 14q31.3 1 GALC,GPR65
15q 15q21.2 1
16p 16p13.3 1
16q 16q12.1a 11 11 ZNF423, CYLD, SALL1
16q12.2a 13 13 CHD9, FTS, RBL2, BC003583, IRX3, IRX6
16q13a 8 8 MT1E, MT1G, MT1X, MT1A, MT1B, MT1F, MT1H,
MT2A, MT3, MTM, MT1JP, MT1M,
NUP93,C16orf50, GPR56, KATNB1, GPR114,
GPR97, CNGB1, C16orf50, KIFC3, BC082977,
KATNB1
16q21a 20 20 CDH8, CDH11
16q22.1a 2 2 LOC497190, MGC34761, BC063633, LOC348174,
WWP2, COG4, FUK, SF3B3, ST3GAL2
16q22.3a 6 6 AY358233,AP1G1,PHLPPL,LOC55565,
KIAA0174,DHODH,LOC55565,
PMFBP1,HP,DHX38,TXNL4B,HPR
16q23.1a 19 19 ADAMTS18, WDR59, FA2H, ZNRF1, KIAA1576,
CLEC3A, WWOX, MAF
16q23.2a 1 1
16q23.3a 3 3 CDH13, HSBP1
16q24.1a 5 5 KIAA0703, KIAA1609, ZDHHC7, KIAA0513,
FAM92B, AK127184, IRF8
16q24.2a 2 2
16q24.3a 1 1 AK023048, AK092264, ANKRD11, AK125549
17p 17p13.3a 1 1 CARKL, P2RX5, CR624034, TMEM93, CTNS,
ITGAE, TAX1BP3, HSA277841, GSG2
17p13.2 1 ZZEF1, AK074369, AK128386, ATP2A3, CYB5D2
17p13.1a 3 8 MYH10, CCDC42, FLJ35773, WDR16, STX8,
GAS7, C17orf48, MYH2, LOC388335,
MYH3,SCO1, FLJ45455
17p12a 3 3 AK092009, MYOCD, KIAA0672, ELAC2
18p 18p11.32 1
20p 20p13a 1 1 DEFB125, BC048429, DEFB128, DEFB126,
DEFB129, DEFB127, DEFB32
22q 22q12.1 2 1 SEZ6L, AB051436, AK172861, KREMEN1,
HS747E2A
22q12.3a 3 2 RAXLX
Xp Xp11.3 1
Cytobands in bold contain one or more statistically significant SNP(s) that have differential LOH frequencies that differentiate ILC from IDC.
aCytobands containing some (or all) common SNPs with high frequency LOH in both ILC and IDC.
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Figure 1. Average LOH Frequencies across the genome or by chro-
mosomal arm in ER-positive ILC and IDC tumors. (A) A box plot of frac-
tional allelic loss calculated for all informative SNPs in the genome (FAL;
ratio of the # LOH and # informative SNPs) for tumors grouped by histo-
logical subtype. (B) Average FAL by chromosomal arm for ER-positive
ILC (red bars) and IDC (blue bars) tumors. The line represents 25% FAL.
(C) Box plots of FAL across the genome for each ER-positive ILC and
IDC tumors stratified by tumor size, mitotic rate, and DNA content. The
median FAL for ILC and IDC tumors are shown as the bold line in the
box with the 1st and 3rd quartiles as the lower and upper bars of the
box. Two-sample t test was used to calculate the P values for genome-
wide and chromosomal-arm FAL comparisons. The F-test was used to
calculate the P values for genome-wide FAL for tumors stratified by tu-
mor size.
Genes, Chromosomes & Cancer DOI 10.1002/gcc
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not significant. Taken together, these results indi-
cate that significant differences in LOH frequency
between ILC and IDC tumors can be detected in
specific chromosomal arms.
We used categorized copy number data (see
Materials and Methods) to assess genomic altera-
tion events associated with the allelic loss on the
six chromosomal arms with statistically significant
differences in LOH frequencies between ILC and
IDC. We observed the majority of LOH events to
be associated with no copy number change (89 and
82%), for ILC and IDC respectively, with a lower
percentage associated with copy number loss (11
and 17%), and dramatically lower with copy num-
ber gain (0.14 and 0.53%) for these six chromo-
somal arms, suggesting that the mechanism for the
majority of observed LOH, associated with no
copy number change, on these six chromosomal
arms is the result of an initial deletion of one allele
followed by reduplication of the remaining allele.
Differential LOH Frequency in Relation to Tumor
Size, Mitotic Rate, or DNAContent
Three clinical characteristics, tumor size, mitotic
rate, and DNA content, distinguished ILC and
IDC tumors (Table 1). We stratified the tumors
based on these three clinical characteristics and
compared both genome-wide and chromosomal
arm-specific FAL for ILC and IDC tumors.
We compared the whole genome FAL for ILC
and IDC tumors grouped in AJCC tumor size cate-
gories (T1a/T1b, T1c, and T2/T3) and found a
strong correlation between increased genome-wide
FAL and tumor size (P < 0.001) for the three size
categories in IDC tumors (Fig. 1C). This correla-
tion was not observed in ILC tumors (P 5 0.210).
The average FAL for individual chromosomal arms
were determined for the tumor size groups to
grossly map where there may be similarities or dif-
ferences in the quantities and locations of these
LOH events. We observed no significant differen-
ces in FAL at the chromosomal arms for ILC and
IDC in the T1a/T1b size group. However, there
were significant differences in three chromosomal
arms (7p, 8p, 16q) in the T1c group and in nine
chromosomal arms (3p, 5q, 8p, 9p, 13q, 15q, 18p,
20p, 20q) in the T2/T3 group (Table 3). Overall
these results indicate divergence of frequency and
location of genomic alterations between the sub-
types with increasing tumor size.
ILC tumors generally demonstrate low mitotic
activity. For this study, 92% of the ILC tumors
were in this category. We observed a significant dif-
ference (P < 0.001) in the genome-wide FAL
between low versus inter/high mitotic rate IDC
tumors, whereas ILC tumors stratified by mitotic
rate did not show this difference (P 5 0.400) (Fig.
1C). We observed significant differences in FAL
between ILC and IDC for chromosome arms 1p,
7p, 8p, and 12q in the low mitotic rate group, and
in 4q, 5q, 7q, 16q, 17q, 19p, 20p, and 20q in the
high mitotic rate group (Table 3).
DNA index is a quantitative measure of DNA
content and was determined for all tumors during
the flow sorting step. For the 77 ILC and 89 IDC
tumors, 62 and 52 were diploid/near diploid and 15
and 37 were aneuploid, respectively. When tumors
of each histological subtype were stratified by
ploidy, we observed the aneuploid tumors of both
ILC and IDC had a higher median whole genome
FAL than the diploid/near diploid tumors in that
subtype (Fig. 1C). This difference between ploidy
groups was statistically significant for IDC tumors
(P 5 0.001), but not significant for ILC tumors
(P 5 0.107). Two chromosomal arms (7p and 12q)
showed significant differences (P < 0.05) in FAL
between diploid ILC and IDC. Five chromosomal
arms (8p, 13q, 16q, 20p, and 20q) showed signifi-
cant difference (P < 0.05) in FAL between aneu-
ploid ILC and IDC (Table 3).
Identification of differences in LOH frequency
and locations between ILC and IDC tumors
measured by both whole genome and chromo-
somal arm FAL is most dramatic when comparing
tumors with increased tumor size, mitotic rate,
and ploidy.
Identification of Loci with Differential LOH
Frequencies for ER-Positive ILC and IDC Tumors
In addition to the observed differences between
ILC and IDC in overall or chromosome-arm spe-
cific FAL, we identified specific SNPs that showed
differential LOH frequencies in ILC and IDC. We
found that 9.5% (n 5 544) of SNPs with >25%
informativity had statistically significant (P < 0.05)
differences in LOH frequencies between ILC and
IDC (Supplemental Data 2). This percentage of
SNPs is much greater than the 5% expected if
none of the SNPs is associated with subtype.
These SNPs are distributed throughout the ge-
nome (Fig. 2A) and of the 544 SNPs, 466 (86%)
had a higher frequency of LOH in IDC, and 78
SNPs (14%) had a higher frequency of LOH in
ILC (Table 4). The LOH frequencies for individ-
ual SNPs in each subgroup are plotted along the
genome in Figure 2B to illustrate the differences
in frequencies for the two subgroups at these
SNPs.
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Hierarchical clustering was performed using the
544 SNPs showing differential LOH to evaluate
common patterns of LOH events and their associa-
tion with tumor characteristics such as histology,
grade, tumor size, mitotic rate, and ploidy (Fig.
2C). The dendrogram shows that the 166 tumors
form four major groups. Tumors in Group 1 are
exclusively IDC, usually large (>2.0 cm), and have
LOH primarily in 3p, 5q, and 13q. Group 2 consists
primarily of IDC tumors (67%), the majority of
Figure 2. Genomic Distribution and Patterns of LOH Differentiates
ER-positive ILC and IDC Tumors. (A) The genomic distribution of all
SNPs whose LOH frequency differs significantly between IDC and ILC
(P values < 0.05) (Likelihood Ratio Test). The y-axis is the -Log10(P
value) reflecting the P values of SNPs with significant differences in the
frequency of LOH between ILC and IDC tumors. The red bars above
the x-axis represent SNPs with a significantly higher frequency of LOH
in ILC than IDC and the blue bars below the x-axis represent SNPs
with a significantly higher frequency of LOH in IDC than ILC. Chromo-
somal locations are indicated. (B) Whole genome plots of the FAL for
SNPs (P < 0.05) illustrating the relative differences in FAL frequency at
each. The top plot represents the differential SNPs with a higher fre-
quency of LOH in ILC and the bottom plot represents the differential
SNPs with a higher frequency of LOH in IDC The red bars represent
the FAL of ILC tumors and the blue bars represent the FAL of IDC
tumors. (C) Hierarchical clustering of the differential SNPs (P < 0.05).
Tumors are grouped into four major groups based on their patterns of
LOH and retention of heterozygosity (ROH). Tumor characteristics
such as histological subtype (red is ILC and blue is IDC), grade (dark to
light green represent high to low grade, respectively), size (dark to light
purple represent T2/3 to T1a/b, respectively), mitotic rate (dark and
light violet represent high/intermediate to low, respectively), and ploidy
(aneuploid orange and diploid yellow) are indicated above the dendro-
gram. A pink block in the clustermap represents LOH, a blue block rep-
resents ROH; a white block represents a non-informative SNP.
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TABLE 4. Cytoband Location of SNPsa with Differential Frequencies of LOH for ER-Positive ILC and IDC Tumors
Chromosomal
arm
Higher frequency of LOH in ILC Higher frequency of LOH in IDC
Cytogenetic
band
Genes 100 kb up or
downstream of SNPs
with differential LOH
frequencies Cytogenetic band
Genes 100 kb up or downstream of SNPs
with differential LOH frequencies
1p 1p34.3, 1p13.2 CSMD2, C1orf94,
ADORA3, ATP5F1,
RAP1A, WDR77,
C1orf162
1p31.3, 1p31.1, 1p22.1,
1p13.3
AK124028, GNG12, ST6GALNAC3,
ABCA4, ARHGAP29, PSRC1, AK127086,
AK127745, MYBPHL, CELSR2, PSMA5,
SORT1
1q 1q23.1, 1q23.2,
1q25.1,
1q31.11q32.1,
1q41, 1q42.12
OR10K2, CRP, APCS,
TNR, IPO9, NAV1,
BX648460, SUSD4,
C1orf65, ENAH
1q25.2, 1q31.1, 1q41,
1q42.2
PAPPA2, C1orf136, DISC1
2p 2p24.1, 2p21,
2p16.1
2p25.1, 2p24.1, 2p16.1,
2p14, 2p12
RSAD2, RNF144, LOC129607, AK096196,
LRRTM4
2q 2q14.3, 2q36.1 CNTNAP5, FARSLB,
MOGAT1
2q11.2, 2q12.1, 2q14.3,
2q22.1, 2q23.1,
2q24.1, 2q24.3,
2q33.1, 2q33.3, 2q34,
2q36.2, 2q36.3,
2q37.1
NPAS2, CNTNAP5, LRP1B, EPC2, MBD5,
GALNT13, COBLL1, HECW2, STK17B,
HECW2, MPP4, ALS2, AK131512,
ALS2CR7, KIAA0971, MDH1B, KIAA0971,
CPS1, LANCL1, DOCK10, FLJ20701,
DNER, AK128274, SP110, SP140,
3p 3p26.3, 3p26.2, 3p26.1,
3p25.2, 3p24.3,
3p24.2, 3p24.1, 3p23,
3p22.3, 3p22.1,
3p21.31, 3p14.3,
3p14.2, 3p14.1, 3p13,
3p12.3, 3p12.1
SUMF1, AK058041, AK094424, ATG7,
VGLL4, TIMP4, RPL15, UBE2E1, NKIRAS1,
NR1D2, RPL15, NKIRAS1, MYRIP,
SEC22L3, VIPR1, LYZL4, LARS2, WNT5A,
CAST1, FHIT, PTPRG, SUCLG2,
FAM19A1, LOC401072, ROBO1, IGSF4D,
3q 3q13.12, 3q26.33 CD47,IFT57, FXR1,
DNAJC19
3q24, 3q25.2, 3q26.1 PLSCR1, P2RY1, ARL14 , PPM1L, PPM1L,
4p 4p15.33 BC036758 4p15.33, 4p15.32,
4p15.1, 4p14
APBB2
4q 4q21.21, 4q28.3 BX648337, RASGEF1B 4q24, 4q25, 4q26,
4q28.1, 4q28.3,
4q31.21, 4q31.3,
4q32.1, 4q33, 4q34.2,
4q34.3, 4q35.1,
4q35.2
BANK1, TACR3, HADHSC, LEF1, CYP2U1,
MGC26963, SPRY1,IL15, AF494508,
USP38, GAB1, PET112L, DCHS2,
GUCY1A3, AK172805, C4orf18,
FLJ11155, NEIL3, AGA, NEIL3, FAT,
MTNR1A
5p 5p13.1, OXCT1 5p15.31, 5p13.1 ADCY2, FLJ40243, C7
5q 5q23.2 5q11.2, 5q12.1, 5q12.3,
5q13.1 5q13.3,
5q14.1, 5q14.2,
5q14.3, 5q15, 5q21.1
5q21.2, 5q21.3,
5q22.1, 5q22.2,
5q23.1, 5q23.2,
5q23.3, 5q31.1,
5q31.2, 5q31.3, 5q32,
5q33.2, 5q33.3, 5q34,
5q35.1, 5q35.2
KCTD9, ARL15, AJ973643, ESM1, GZMK,
FLJ37927, LOC493869, GZMA, UNG2,
R7BP, ADAMTS6, AK130467, FLJ13611,
SGTB, BC047475, TRIM23, PPWD1,
FKSG14, AK057601, LOC375449,
FLJ35779, LOC441087, AK128395, TBCA,
OTP, MSH3, RASGRF2, XRCC4,
MGC23909, ARTS-1, LRAP, LNPEP,
AF119888, SLCO6A1, SLCO4C1,
MAN2A1, CAMK4, WDR36, APC,
AK125966, MCC, TSSK1, YTHDC2,
TNFAIP8, DMXL1, SNCAIP, CSNK1G3,
FLJ36090, AK093561, LMNB1, MARCH3,
AK026965, H2AFY, PCDHGB7,
PCDHGA10, PCDHGB5, PCDHGB2,
PCDHGA2, PCDHGC3, PCDHGA12,
PCDHGB4, TAF7, PCDHGA8,
PCDHGA1, PCDHGA11, PCDHGA3,
PCDHGA4, PCDHGA5, PCDHGA6,
PCDHGA7, PCDHGA9, PCDHGB1,
PCDHGB3, PCDHGB6, PCDHGC4,
PCDHGC5, SLC25A2, HB-1, POU4F3,
TCERG1, POU4F3, TCERG1, AK172724,
CYFIP2, MGC27121, AK128840,
ADRA1B, TTC1, GABRG2, MAT2B,
HMMR, WWC1, SLIT3, FLJ20364, DOCK
(Continued)
TABLE 4. Cytoband Location of SNPsa with Differential Frequencies of LOH for ER-Positive ILC and IDC Tumors (Continued)
Chromosomal
arm
Higher frequency of LOH in ILC Higher frequency of LOH in IDC
Cytogenetic
band
Genes 100 kb up or
downstream of SNPs
with differential LOH
frequencies Cytogenetic band
Genes 100 kb up or downstream of SNPs
with differential LOH frequencies
6p 6p24.1, 6p21.2,
6p21.1
PHACTR1, MDGA1,
AK126965,
AK127725, C6orf129,
SLC35B2, AF090903,
HSP90AB1, NFKBIE,
MGC33600, SPATS1,
CDC5L, AARSL
6p25.3 GMDS
6q 6q14.1, 6q21,
6q22.2,
6q23.3,
6q25.2,
6q25.3, 6q26
HTR1B, SEC63,
OSTM1, DCBLD1,
ROS1, HBS1L,
ALDH8A1, SYNE1,
MYCT1, RSHL2,
TAGAP, PNLDC1,
ACAT2, MAS1,
MRPL18, TCP1,
MAP3K4, AK094629
6q12, 6q13, 6q15,
6q16.3, 6q26
CD109, MAP3K7, PARK2
7p 7p15.2, 7p15.1,
7p14.3,
7p14.2, 7p14.1
HIBADH, CREB5,
CPVL, KIAA0241,
LOC441208, PTHB1,
FLJ22313, SEPT7
7p21.3, 7p21.2
7q 7q21.13, 7q21.3,
7q31.1,
7q31.33
PFTK1, PON2, PON1,
PON3, FOXP2,
POT1, GPR37, GRM8
7q22.3, 7q31.1, 7q33 AK127860, PIK3CG, PRKAR2B, EXOC4,
AKR1B1, SLC35B4, FLJ32786
8p 8p23.3, 8p23.2, 8p23.1,
8p22, 8p21.3, 8p21.2,
8p21.1, 8p12
MYOM2, ANGPT2, MCPH1, AF217970,
AK126737, AY461701, PPP1R3B, THEX1,
AY203962, PINX1, SOX7, RP1L1,
AB073660, XKR6, AJ307469, C8orf16,
C8orf15, AJ291678, AK131319,
BC080558, C8orf13, BLK, SGCZ,
BC098128, FGF20, EFHA2, AY176665,
PSD3, SLC18A1, LPL, ATP6V1B2, LZTS1,
C8orf58, PEBP4, BIN3, KIAA1967,
SORBS3, EGR3, PPP3CC, PDLIM2,
FLJ14107, DOCK5, AK130123, AY700779,
EBF2, ELP3, ZNF395, PNOC, RC74,
FLJ21616, EXTL3, WRN, PURG, FUT10,
CR596972
8q 8q21.11,
8q21.13,
8q21.3
TPD52, TMEM64,
EFCBP1
8q12.1, 8q12.2, 8q12.3,
8q13.2, 8q21.3,
8q23.1, 8q24.22
IMPAD1, RAB2, CHD7, ZFPM2, ADCY8,
ST3GAL1
9p 9p24.2, 9p24.1, 9p23,
9p22.2, 9p21.3,
9p21.2, 9p21.1,
9p13.3, 9p13.1
SMARCA2, CR595322, GLIS3, TPD52L3,
UHRF2, JMJD2C, MPDZ, SH3GL2, MLLT3,
KIAA1797, IFNA5, IFNA21, IFNA14,
IFNA10, IFNA16, IFNW1, IFNA7, IFNA4,
IFNA17, MTAP, ELAVL2, TUSC1,
LRRN6C, AF370382, AY358408,
C9orf127, NPR2, OR2S2, C9orf128,
SPAG8, HINT2, SHB
9q 9q21.33, 9q31.1,
9q31.2
NTRK2, TMEFF1,
LOC347273, PRG-3,
PPP3R2, GRIN3A
9q21.2, 9q21.31 GNAQ
10p 10p15.3, 10p15.1,
10p14, 10p13,
10p12.33, 10p12.31,
10p12.1, 10p11.23,
10p11.22
ZMYND11, DQ335455, DIP2C, PFKFB3,
AK128185, CCDC3, CAMK1D,
SLC39A12, MRC1, PLXDC2, KIAA1217,
SVIL, ARHGAP12
(Continued)
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TABLE 4. Cytoband Location of SNPsa with Differential Frequencies of LOH for ER-Positive ILC and IDC Tumors (Continued)
Chromosomal
arm
Higher frequency of LOH in ILC Higher frequency of LOH in IDC
Cytogenetic
band
Genes 100 kb up or
downstream of SNPs
with differential LOH
frequencies Cytogenetic band
Genes 100 kb up or downstream of SNPs
with differential LOH frequencies
10q 10q21.1 C10orf70, IPMK 10q11.21, 10q21.1,
10q21.3, 10q22.3,
10q23.31
RET, PCDH15, RAI17, LIPA, IFIT2, IFIT3,
CH25H,
11p 11p15.4, 11p15.3,
11p15.2, 11p15.1,
11p14.3, 11p11.2
RRM1, STIM1, TRIM6, TRIM6-TRIM34,
TRIM34, UBQLN3, MGC20470, SYT9,
STK33, LOC58486, MICAL2, DKK3,
LOC387755, AB231748, MRGPRX2,
PHF21A, PTPRJ
11q 11q11, 11q25 OR5M10, OR5M8, HNT, OPCML
12p 12p13.32, 12p13.2,
12p13.1, 12p12.2
CCND2, C12orf5, FGF23, FGF6, BCL2L14,
GRIN2B, SLCO1B3, LST-3TM12,
SLCO1C1
12q 12q15, 12q23.3 CPM, HCFC2, NFYB 12q14.1, 12q21.1
13q 13q12.11, 13q12.3,
13q14.11, 13q14.3,
13q21.1, 13q21.32,
13q21.33, 13q22.3,
13q31.1, 13q31.2,
13q31.3, 13q32.1
13q32.31 ,3q33.1
CRYL1, BC071810, ZDHHC20, FLJ14834,
MGC40178, AY116215, AY116216,
FLJ40919, EPSTI1, DLEU7, FLJ30707,
GUCY1B2, LECT1, PCDH8, PCDH17,
PCDH9, DACH1, GPC6, DOCK9, PCCA,
BC001077, FGF14
14q 14q11.2, 14q22.2,
14q23.1, 14q23.2,
14q24.1, 14q24.2,
14q24.3, 14q31.1,
14q31.3, 14q32.11,
14q32.13, 14q32.2,
14q32.33
FLJ10357, HNRPC, BC031469, CR617382,
CR618390, ZNF219, RNASE7, BC035680,
BC063432, MGC40069, PLEKHC1,
DDHD1, FLJ46156, PPP2R5E, RHOJ,
GALNTL1, EXDL2, ERH, SLC39A9,
SIPA1L1, RGS6, AF113687, AF130112,
DPF3, WDR21A, TTLL5, TGFB3,
MGC16028, NRXN3, DIO2, TSHR,
GTF2A1, AK130927, CHES1, BC069658,
SERPINA9, SERPINA11, SERPINA5,
SERPINA3, SERPINA4, SERPINA12,
DICER1, CLMN, FLJ45244, C14orf68,
SLC25A29, WDR25, CR607410, YY1,
WARS, AK124507, ZFYVE21, KNS2,
XRCC3, PPP1R13B
15q 15q26.1 AK124722, SV2B,
SLCO3A1
16p 16p13.2,
16p13.13
A2BP1, NUBP1, EMP2,
FLJ32871
16q 16q12.1,
16q12.2,
16q13,
16q22.3,
16q23.1
ZNF423, BC003583,
BC003583, IRX3,
IRX6, C16orf50,
GPR56, KATNB1,
GPR114, GPR97,
AY358233, AP1G1,
PHLPPL, LOC55565,
MAF
16q23.1 KIAA1576
17p 17p13.1 GAS7, FLJ45455
17q 17q11.1 WSB1, KSR1 17q11.2, 17q12,
17q21.2, 17q25.3
SSH2, RAB11FIP4, ACCN1, GAS2L2, AP2B1,
C17orf50, MMP28, RASL10B, TCF2,
KRT25A, KRT25D, KRT12, KRT10, KRT24,
KRT25C, KRT25B, FLJ21865, LOC146713,
raptor
18p 18p11.31, 18p11.22,
18p11.21
AK126828
(Continued)
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which were of high or intermediate grade. Tumors
in this group had LOH in 3p, 8p, 13q, and 16q.
Group 3 is predominantly IDC tumors (67%) of in-
termediate grade with several large (>2.0 cm) ILC
diploid/near diploid tumors. The tumors in this
group had LOH in 3p, 6q, 13q, and 16q. Group 4
consists predominantly of ILC and low-grade IDC
tumors, together accounting for 75% of the tumors
in this group. Tumors in this group had an overall
lower frequency of LOH in these 544 SNPs but
virtually all showed LOH in 16q and a subset addi-
tionally had LOH in 8p.
DISCUSSION
In this study of ER-positive breast cancer, we
used the Mapping 10K SNP microarray to assess
the similarities and differences of allelic imbalance
in ILC and IDC tumors across the genome. This
study was unique in that the participants were
drawn from a population-based setting, and tumors
TABLE 4. Cytoband Location of SNPsa with Differential Frequencies of LOH for ER-Positive ILC and IDC Tumors (Continued)
Chromosomal
arm
Higher frequency of LOH in ILC Higher frequency of LOH in IDC
Cytogenetic
band
Genes 100 kb up or
downstream of SNPs
with differential LOH
frequencies Cytogenetic band
Genes 100 kb up or downstream of SNPs
with differential LOH frequencies
18q 18q11.2, 18q12.1 DSG1, DSC1
19p 19p13.3, 19p13.12 ZNRF4, PGLYRP2, AK024488, AK131404,
BC030281, BRD4, AKAP8, AKAP8L
19q 19q13.12, 19q13.2,
19q13.31, 19q13.33,
19q13.42, 19q13.43
AF289566, ZNF565, AK090827, COX7A1,
ZNF146, KIAA1559, ZNF420, AK098695,
BC026081, ZNF585A, AF090927, EIF3S12,
AK094707, AK126566, LGALS7, ACTN4,
ECH1, LGALS4, MAP4K1, CAPN12,
ZNF180, ZNF229, KLK4, KLK3, KLK2,
KLK15, KLK1, BC033237, BC066878,
GPR32, CLEC11A, SHANK1, ACPT,
MGC13170, KLK11, KLK7, KLK6, KLK5,
AY551001, AY646152, KLK13, KLK12,
KLK14, KLK10, KLK8, KLK9, ATPBD3,
UNQ3033, PRKCG, CACNG8, CACNG7,
CACNG6, LILRB1, LILRA2, FLJ00060,
LILRB4, LAIR2, LILRA1, ZNF272, AURKC,
LOC390980, ZNF264, USP29, IM3,
ZNF543
20p 20p12.3, 20p12.2,
20p12.1, 20p11.23,
20p11.21
BMP2, PLCB1, AK126221, PLCB1, JAG1,
BTBD3, C20orf38, AK074473, AK075271,
SLC24A3, THBD, CD93, GGTLA4,
ENTPD6, CR600960, CR936765, PYGB,
C20orf22
20q 20q11.23, 20q12,
20q13.13, 20q13.2,
20q13.31, 20q13.32
C20orf132, RPN2, GHRH, SRC, MANBAL,
PTPRT, PTPN1, C20orf175, ZFP64,
AK096426, RAE1, RNPC1, SPO11,
AK128005,
21q 21q22.3 AF289552, UMODL1,
TFF3, ABCG1,
U34919
21q22.11, 21q22.13 KRTAP19-1, KRTAP19-4, KRTAP19-5,
KRTAP19-7, AB096950, KRTAP6-2,
AB096956, KRTAP20-2, AB096958,
KRTAP19-2, KRTAP22-1, KRTAP20-1,
KRTAP6-1, KRTAP6-3, KRTAP19-3,
KRTAP19-6, TIAM1, DSCR6, TTC3,
HLCS, PIGP
22q Xp22.31, Xp11.4 22q11.21 LZTR1, SLC7A4, DKFZp434K191,
BC063553, P2RXL1, CR600536,
LOC400891, THAP7, MGC16703,
FLJ42953
Xq Xq22.1 BEXL1, TCEAL5, BEX2, TCEAL8
SNPs whose LOH frequency differs significantly between IDC and ILC (P-values < 0.05 based on the likelihood ratio test).
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were flow cytometrically sorted to provide a
genomic profile with little or no contamination
from normal cells. To our knowledge, this is the
largest set of lobular breast cancers assessed for
LOH by genome-wide SNP analysis.
Frequent Sites of LOH Common to Both Subtypes
of ER-Positive Tumors
We identified genomic regions with a high fre-
quency of LOH (50% FAL) in ILC and IDC
tumors and show that there are several regions
with an overall high frequency of LOH regardless
of subtype (11q, 16q, and 17p) (Table 2). Previous
studies have reported allelic imbalance in regions
on these chromosomal arms and suggested that
they are components of early events in breast can-
cer formation (Fujii et al., 1996; Ando et al., 2000).
Because the majority of these reports focused on
IDC tumors, and our study consists of a near equal
number of IDC and ILC tumors, our data both
complement and add to what was previously
reported and suggest that these are events that are
common to ER-positive breast cancers regardless
of histological subtype.
We identified several sites of high-frequency
LOH containing genes (within 100 kb up or down-
stream of the SNP) that have been implicated in
tumorigenesis, including those involved in metas-
tasis, GPR56 (16q12.2) (Xu et al., 2006); DNA
damage/integrity, CHEK1 (11q24.2) (Petermann
et al., 2006); and tumor suppression,WWOX (16q23.1)
(Ramos and Aldaz, 2006) and RBl2 (16q12.2)
(Jackson and Pereira-Smith, 2006) (Table 2). These
findings are preliminary and further studies will be
pursued to confirm the role of these genes in breast
cancer
It is apparent from our study and many others
that 16q loss is a common and likely early event in
ER-positive ILC and IDC breast cancer. In a high-
resolution assessment of gain and loss on 16q using
array CGH virtually all of the 30 ILC tumors
tested showed loss of 16q distal to approximately
57.5 Mb (Roylance et al., 2006). Loss of the 16q
arm was reported in 100% of 24 tumors containing
both ILC and lobular carcinoma in situ (LCIS)
(Hwang et al., 2004). Low-grade IDC also showed
frequent 16q loss and only subsets of high grade
IDC exhibited loss at 16q (Roylance et al., 1999,
2006).
Aside from the morphological differences
between ILC and IDC, one of the most estab-
lished molecular distinctions is the expression of
the E-cadherin protein (Berx et al., 1995). In this
study, we failed to observe a significant difference
in the frequency of LOH for the SNPs neighboring
to the CDH1 gene (16q22.1) between ILC and
IDC tumors (94 and 81% upstream and 91 and
90% downstream of the CDH1 gene for ILC and
IDC, respectively). The loss of E-cadherin protein
expression in ILC tumors has been linked to
LOH, mutation, hypermethylation, and transcrip-
tional regulation (Korkola et al., 2003; Zhao et al.,
2004). Thus our data confirm earlier observations
that loss of E-cadherin expression in ILC cannot
be attributed solely to allelic loss, but must be the
outcome of additional events that contribute to the
loss of protein expression in ILC specifically.
Differential LOH Frequencies for ER-Positive ILC
and IDC Tumors
In an earlier study using array CGH, we found
that ER-positive ILC had a slightly higher overall
frequency of genomic alterations (copy number
gains and losses) than IDC tumors (Loo et al.,
2004). In this study, we observe an overall lower
frequency of LOH in ILC than IDC tumors. How-
ever, a small number of ER positive ILC tumors
(n5 15) were included in the previous study, which
likely accounts for the difference in the results.
Larger sample size in this study also allowed us
to stratify the two histological subtypes by tumor
size, mitotic rate, or DNA content and compare
whole genome FAL quantities of ILC and IDC
tumors. We observed a statistically significant trend
for IDC tumors to have higher overall FAL with
increasing tumor size, mitotic rate, and DNA con-
tent, whereas ILC tumors did not (Fig. 1). These
results indicate a fundamental difference in the dy-
namics and accumulation of LOH events between
ILC and IDC, especially in large, highly prolifera-
tive tumors with a high DNA content.
When ILC and IDC were compared for FAL per
chromosomal arm, IDC tumors had significantly
more FAL than ILC tumors in 3p, 5q, 8p, 9p, 20p,
and 20q (Fig. 1). The most discriminating differ-
ence in FAL was on 8p. IDC tumors had signifi-
cantly higher frequencies of LOH at the SNPs on
8p with and without stratification of tumors. Loss
on 8p was identified in earlier studies using CGH
and microsatellite markers in IDC tumors and pro-
posed this location to be a potential site of tumor
suppressor genes (Anbazhagan et al., 1998). We
identified several differential SNPs in 8p neighbor-
ing genes (within 100 kb up or downstream)
involved in DNA-damage response and integrity
including BRIT1/MCPH1 (8p23.1) involved in reg-
ulating the expression of CHK1 and BRCA1 and a
proposed tumor suppressor in the ATM/ATR path-
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way (Xu et al., 2004; Rai et al., 2006), and WRN
(8p12), a key regulator of double-strand break
repair (Chen et al., 2003), and PINX1 (8p23), a pu-
tative telomerase inhibitor shown to have reduced
expression in gastric cancer (Banik and Counter,
2004; Kondo et al., 2005). Perturbation of the pro-
tein expression, often associated with allelic imbal-
ance, of one or more of these genes in IDC may
contribute to the initiation and maintenance of
increased numbers of genomic alterations associ-
ated with aneuploidy. This might be one explana-
tion for the lower levels of aneuploidy observed in
ILC tumors.
Similar to 8p, 5q showed more frequent LOH in
IDC than ILC, both with and without stratification
into size and mitotic-rate categories. Other studies
have also identified genomic alterations on 5q to
be associated primarily with ER-negative IDC
breast tumors (Loo et al., 2004; Wang et al., 2004).
The IDC tumors in Group 1 with LOH at 5q could
represent a small subset of ER-positive IDC
tumors with genomic profiles that are more similar
to ER-negative IDC tumors. These tumors also
showed little or no LOH on 8p (Fig. 2C). Two
genes involved in DNA damage response and in-
tegrity, XRCC4 (5q14.2) (Lee et al., 2003) and APC
(5q22.2) (Jaiswal et al., 2005) neighbor individual
SNPs with significantly different frequency of
LOH by histological subtype and may contribute
to genomic instability in this subset of IDC
tumors.
The majority of ILC and low-grade IDC tumors
(Fig. 2C) appeared to have little or no LOH at the
544 distinguishing SNPs in 5q and 8p and a
marked decrease in LOH events on other chromo-
somes. These data support an earlier observation
that ILC and low-grade IDC tumors have fewer
genomic alteration events, with the exception of
allelic loss at 16q, which occurs at a higher fre-
quency in ILC and low-grade IDC tumors
(Buerger et al., 1999). We observed a higher per-
centage of LOH across 16q in ILC (86%) and low-
grade IDC tumors (82%) compared to (77%) for
inter/high grade IDC. In addition, similar to what
we observed with Group 4 (Fig. 2C), Fridlyand et
al. (2006) observed high levels of 16q loss in a sub-
set of ER-positive IDC tumors with low levels of
whole genome copy number changes based on
hierarchical clustering. They observed this subset
to be associated with best patient outcome.
We believe that the reported genomic alteration
events in IDC and ILC tumors reflect sites of
allelic imbalance that are either shared or differen-
tiate these two ER-positive histological subtypes
of breast cancer. Although there are limitations to
our study, including the moderate resolution of the
array (newer versions of the array provide a more
complete coverage with over 900K SNPs) and
modest informativity (34%) of the SNPs on the
array, our results help further to define the geno-
type of lobular breast cancer. These results can be
used in future studies to help understand possible
molecular events underlying the increased inci-
dence of ILC and the relationship of ILC and use
of combined hormone replacement therapy.
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